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The monitoring of CD4+ cell counts are a basis for assessing the 
effectiveness of most HIV treatments. Understanding the way CD4+ cells 
change over time could provide insight into the way Patients respond to 
treatment and how effective treatment is with time. In this study, we obtained 
secondary data from the HIV/AIDS Monitoring Program at the Builsa 
District hospital, in which patients were enrolled and their CD4+ cell counts 
were regularly monitored and thus generating repeated measures of their 
CD4+ cell counts. The purpose of the study was to investigate some 
plausible determinants of change in CD4+ cell count. Mixed effects 
modelling approach was used for modelling the CD4+ cell counts of the 
patients. The results showed that, the correlation between CD4+ cell counts 
at different times had a first order autoregressive moving average variance-
covariance structure. The Initial CD4+ cell count of a patient, the duration of 
treatment and the drug type used in the treatment, were the factors that 
significantly determined a patient’s current CD4+ cell count. 
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1.0. Introduction  
Human Immunodeficiency Virus (HIV) is a lentivirus that causes 
Acquired Immunodeficiency Syndrome (AIDS) by reducing a person’s 
ability to fight infection. HIV attacks an immune cell called the CD4+ cell 
which is responsible for the body’s immune response to infectious agents. 
An uninfected individual has around 1100 CD4 cells per millilitre of blood. 
This CD4+ cells, decrease in number with time from the HIV virus, so that an 




infected person’s CD4+ cell count can be used to monitor the progression of 
the disease (Diggle et al 1994).  
Since the beginning of the disease, somewhere between 1884 and 
1924 in modern day Kinshasa, in the West  Central African Republic 
(Louise, 2011), about 70 million people have contracted HIV and over 30 
million people worldwide have died of it or related causes (UNAIDS, 2012). 
Antiretroviral Therapy (ART) services have been available to HIV 
patients and the Guidelines from the National AIDS Control Program 
(NACP) recommend that patients should initiate treatment when their CD4+ 
cell count is less than 350 cells/  or when they become symptomatic with 
HIV infection as in WHO stages I to IV. Once a patient enrols on the ART 
treatment, the CD4+ cell count of the patients is examined from time to time 
to check whether there is an increase in its count to a relatively normal level 
(> 500 cells per ) or otherwise (NACP, 2001).  
Many researchers have carried out studies on the change in CD4+ cell 
counts of HIV patients. Several of these studies have look at change from the 
cross sectional point of view without considering the pattern of change over 
the period of study or the obvious possible correlation among successive 
CD4+ counts. For example, Kulkarni et al (2011) and Xiuhong et al (2011) 
both used linear regression models to study some predictors of CD4+ Cell 
Count recovery in HIV-1 positive subjects receiving Antiretroviral Therapy 
and CD4+ T-Cell Counts and Plasma HIV-1 RNA Levels beyond 5 Years of 
Highly Active Antiretroviral Therapy respectively. These studies largely 
assumed that the change in CD4+ cells is linear. Luguterah and Adams 
(2013) however used a longitudinal approach and suggested that the pattern 
of growth in CD4+ cell was not Linear. 
This study therefore took into consideration, the changes in the CD4+ 
cells count over the period of study.  By considering changes over time, the 
longitudinal approach has the added advantage of observing changes more 
accurately, by increasing the power and validity of measuring the change in 
CD4+ cell counts.   
 
2.0 Materials and Method 
Data 
We obtained retrospective data from the HIV/AIDS Monitoring 
Program at the Builsa District hospital in the Upper East Region of Ghana, in 
which patients were enrolled and their CD4+ cell counts initially taken on 
enrolment into the ART program and thereafter, counted every six months. 
This program included individuals who were diagnosed of HIV/AIDS, and 
were enrolled in the centre’s HIV/AIDS Drug Treatment Program between 
the period 2008 and 2012: Our data was restricted to all individuals who had 
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their therapy between January 1, 2008 and December 31, 2012. Patients who 
were 15 years or older at the time of diagnosis, and had enrolled in the ART 
program and had their CD4+ cells counted at least thrice, were considered in 
our study.  
Different drug regimens are usually given to the patients based on 
their medical history: Drugs combinations that were prescribed to the 
patients in this study are; Combivir / Nevirapine (CBV+NVP), Tenofovir / 
Lamivudine / Nevirapine (TDF+3TC+NVP), Combivir/ Efavirenz 
(CBV+EFV) and Combivir / Lopinavir / Ritonavir (CBV+LPV+R) 
Tenofovir/Lamivudine/Efavirenz (TDF+3TC+EFV).  
In all, a total of 139 patients’ formed the sample and were used in this 
study. Other factors of the patient such as age, gender, level of education, 
marital status, religious affiliation and drug regimen issued were also 
obtained and used in this study. 
 
Modelling Approach 
We explored the data using basic descriptive statistics and a profile 
plot of the mean CD4+ cell count over the period of our study. Linear mixed 
effects model was used to model the change in CD4+ cell count over time.  
This modelling approach was used because mixed models take into account 
both the within and between sources of variation, are flexible enough to 
account for the natural heterogeneity in the population, and can handle any 
degree of missing and drop-out data in the data. The general structure for the 
model is 
 ,        
Where 
,       
 Random effect for unit  
Between-unit covariance matrix 
Within-unit covariance matrix  
is an  matrix with  columns, matrix  is an  matrix  
columns. Both matrices  depend on through  Averaging over 
the distribution of the latent random effects , the marginal (population-
average) distribution of is   
), where  
  
The resulting estimated b, the fixed-effect parameter for each 
predictor in this model, represents the average change in CD4+ cell count for 
a unit increase in that predictor. The age of the patient and the Initial CD4+ 




cell count were considered continuous variables. The type of correlation 
between successive CD4+ cell counts is reflected in the covariance structure. 
This was explored using the “smaller is better” criteria of the Akaike 
Information Criteria (AIC) and Bayesian Information criteria (BIC).  The 
selected covariance structure, as well as the pattern of change of the 
CD4+cell count, was used to fit a No-intercept model for the data: Both a 
full and a reduced model were fit to the data. 
 
Results  
The descriptive statistics of the data, showing the distribution of the 
patients across the various levels of the factors considered, as well as their 
minimum and maximum CD4+ cell counts, are shown in Table 1. The 
pattern of Change of the time plot, as shown in figure 1, suggests a 
logarithmic trend of the change in CD4+ cell count. The Akaike's 
Information Criterion (AIC) and Bayesian Information Criterion (BIC) of the 
variance covariance structures model (shown in table 2), suggest that the 
correlation between the CD4+ cell counts at various times followed the first 
order autoregressive moving average (BIC = 4920.6). Thus, even though a 
patient’s CD4+ cell count depended on his/her past CD4+ cell counts, the 
strength of the relationship was stronger with his/her immediate past CD4+ 
cell count, and weakened with increasing time difference between counts.  
We incorporated the logarithmic trend into the linear mixed effect 
model to obtain the parameter estimates, and their significance, of the model 
as shown in Table 3. The table shows that the initial CD4+ cell count, age, 
gender and duration of treatment (in months) are significant determinants of 
the CD4+ cell counts of a patients on ART. The rate of change in CD4+cell 
count, expressed as a logarithmic function (ln(t)) is 105.01 counts per unit 
increase in logarithmic time. This suggests that the rate of increase in CD4+ 
cell count decreases with time.  
A patient’s initial CD4+cell count significantly determined his/her 
current CD4+ cell count at the 5% significance level ( p-value < 0.0001). A 
patient has a 0.4624 CD4+ cell count disadvantage, for every count lower in 
initial CD4, when compared to his/her counterpart. The duration of treatment 
is also shown to significantly determine a Patients CD4+ cell count ( 
) as shown in table 4.4.3, a patients’ CD4+ cell 
count increased by about 40 cells/  every 6 months. This suggested that 
there is strong positive association between CD4+ count and duration of 
treatment (time). The effect of age on change in CD4+ cell count was also 
statistically significant at the 5% significance level. A patient has an average 
of 2.551 count disadvantage for every year older he /she is at the time of 
diagnosis.  
European Scientific Journal   November 2013  edition vol.9, No.33  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
303 
 
There was also significant gender differential among patients that 
were on treatment (p-values < 0.0001): The average CD4+ cell count for 
males is about 29 counts higher than that of their female counterparts. While 
there were no educational differentials in this study, Marital and Religious 
differentials were observed in this study. Only married patients significantly 
differed from the widowed. They had significantly lower CD4+ cell count 
(  -83.58 and p-value = 0.0084) when compared to the widowed. Patients 
who professed Islam or No Religion, had significantly lower change in 
CD4+ count (  = -149.24, p-value = 0.0079 and  -127.79, p-value = 
0.0433 respectively) when compared to those who belonged to the traditional 
religion. 
The general model for patients CD4+ count is given by  
 
With a reduced model for prediction given by 
 
Where Combivir/Nevirapine = CBV+NVP, Tenofovir / Lamivudine / 
Nevirapine = TDF+3TC+NVP, Combivir / Efavirenz = CBV+EFV, 
Combivir / Lopinavir / Ritonavir = CBV+LPV+R and Tenofovir / 
Lamivudine / Efavirenz = TDF+3TC+EFV 
 
Discussions 
We compared the Akaike's Information Criterion (AIC) and Bayesian 
Information Criterion (BIC) for the known covariance structures and chose 
the autoregressive moving average model as the best fit for the covariance 
structure of the CD4+ cell counts based on the information criteria. This 
means that there is a correlation between CD4+ cell counts and that the 
correlation weakened with distance between counts.  Our mixed model 
results showed that the duration of treatment is a significant determinant of a 
Patients CD4+ cell count (as expected of all treatments). This study is in 
contrast with the study by Viviane et al (2009), who showed a decline in 
CD4+ cell count over time among untreated HIV/AIDS patients; the net 
effect of these studies, together with the significance of duration of treatment 
shown in our study, confirms the well accepted fact of the effectiveness of 
the ART. 




The significant gender differentials shown in this study, contradicts 
results from earlier studies by Mair et al (2008) that males were associated 
with significantly lower CD4+ cell counts when compared to females. Our 
results showed that male patients responded to treatment better than females 
which could be a result of socio cultural practises and norms associated with 
gender. 
Consistent with findings by Xiuhong et al (2011), that older men had 
60 fewer CD4+ cells per microliter on average when compared with the 
younger men, our study showed that treatment was less effective for elderly 
patients: This is expected, because it is well known from literature that 
immune function declines with age.  
The importance of early treatment was shown in this study: The 
Initial CD4+ cell count was shown to significantly determine a Patient’s 
CD4+ count. A higher initial CD4+ cell count would result in a better rate of 
recovery of patients on ART: This agrees with findings of Viviane et al 
(2009) and Kulkarni et al (2011).  
Our study did not show any age differentials: While is it conceivable 
that educational level could among other things influence knowledge of, and 
behavioural patterns about HIV/AIDS, and even response to treatment, as 
shown in several studies (McMahon et al., 2011; Upreti, Regmi, Pant and 
Simkhada, 2009; Ho and Loke, 2003) once a Person is diagnosed as having 
the virus and on monitored treatment, any medication taken is not expected 
to act differently on Patients because of their educational status.  
On the marital status of Patients on ART, only married patients CD4+ 
cell counts significantly differed, when compared with the widowed: The 
significantly lower expected CD4+ cell counts for married couples is 
consistent with several studies and could be as a result of reinfection of each 
other.  
The religious differentials shown in this study are not only a 
reflection of the deeply religious Ghanaian society, but also the high 
influence of Religion on the beliefs, attitude and practises on people. It is 
therefore imperative that in the education, treatment and other activities of 
HIV/AIDS in highly religious environments, not only should religious 
concerns be taken into account but also, the support of Religious leaders 
should be sought.  
 
Conclusion  
Generally all the patients that were considered in our study between 
January 2008 and December 2012 had their CD4+ cell count increased at 
different levels after been put on treatment at a certain initial CD4+ cell 
count. The determinants of CD4+ cell counts, as well as the effect of the 
factors studied on patients CD4+ cell count were shown in this study. While 
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this study is useful to guide education to the Public, particularly Patients, and 
also guide policy and management of treatment, further studies are 
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Table 1 Descriptive Statistics of CD4+ Count of Patients 
 Percentage Min (CD4+) Max (CD4+) Age    20-29 21 324 1032 
30-39 42 226 1779 
40-49 18 160 1264 
50-59 12 150 1203 
60-69 7 140 1195 
SEX    Male 81 8 1779 
Female 19 79 935 
EDUCATION    Non 59 51 1203 
Primary 9 172 618 
JHS/middle 14 39 1779 
SHS 10 176 , 1264 
Tertiary 8 8 1195 
Marital status    Divorce 21 39 1779 
Married 41 51 1203 
Single 9 176 1264 
Widow(er) 25 8 1195 
Separated 2 172 618 
DRUG    CBV+EFV 27 244 1264 
CBV+LPV/R 3 180 720 
CBV+NVP 36 281 1779 
TDF+3TC+EFV 14 155 769 
TDF+3TC+NVP 20 238 1203 
RELIGION    Christianity 78 8 1779 
Islam 11 150 1082 
Traditionalist 7 185 634 
Non 4 171 796 
 
 
Figure 1 Profile Plot of mean CD4+ count 





Table 2: Statistics for covariance Structure Models 
Structure AIC BIC 
First order Autoregressive 
AR(1) 4915.6 4920.6** 
Compound Symmetry 4965.8 4970.8 
Variance Component 5134.3 5136.8 
Toeplitz 4917.2 4934.7 
AR (1,1) Moving Average 4913.3** 4920.8 
Heterogeneous Toeplitz 4960.8 4949.3 
Heterogeneous  AR(1) 4915.7 4935.7 
Heterogeneous  Compound 
Symmetry 4952.1 4972.1 
** means Smallest 
 
Table 3: First order Autoregressive AR (1) moving average covariance structure output 
Effect Estimate Standard Error DF t value Pr < |t| 
Initial CD4+ 0.4624 0.07432 372 6.22 <.0001 
Age -2.4551 1.212 372 -2.03 0.0435 
Ln(t) 105.01 17.8722 372 5.88 <.0001 
GENDER      
Female 410.49 105.59 372 3.89 0.0001 
Male 440.16 107.76 372 4.08 <.0001 
Education (compared with tertiary) 
Non 7.1215 48.8301 372 0.15 0.8841 
Primary -87.061 63.3908 372 -1.37 0.1705 
JHS/middle 53.5336 56.5644 372 0.95 0.3445 
SHS 4.5824 59.2541 372 0.08 0.9384 
Marital Status (compared with widowed) 
Divorce -10.465 34.0298 372 -0.31 0.7586 
Married -83.58 31.5647 372 -2.65 0.0084 
Separated -33.627 -33.6269 372 -0.48 0.6299 
Single -93.411 49.6997 372 -1.88 0.061 
DRUG (compared with TDF/3TC/NVP) 
CBV/EFV 45.2674 40.222 372 1.13 0.2611 
CBV/LPV/R 16.0026 72.2657 372 0.22 0.8249 
CBV/NVP 86.3384 38.1768 372 2.26 0.0243 
TDF/3TC/EFV 3.8756 40.9513 372 0.09 0.9247 
RELIGION (compared with Traditionalist) 
Christianity -13.344 38.984 372 -0.34 0.7323 
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Islam -149.24 55.8397 372 -2.67 0.0079 
Non -127.39 62.8247 372 -2.03 0.0433 
 
Table 4: Estimates of reduced model 
  Estimate Standard Error t value Pr >|t| 
Initial CD4+ 0.49511 0.07045 7.028 9.61  
Ln(t) 113.61 18.5267 6.132.15 2.15  
CBV/EFV 289.434 29.572 9.787 <2.0  
CBV/LPV/R 249.045 64.5578 3.858 0.000134 
CBV/NVP 324.722 28.6959 8.881 2.0  
TDF/3TC/EFV 248.552 30.9545 8.03 1.2  
TDF/3TC/NVP 241.186 41.009 5.881 8.85  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
